GILT study: Oral vinorelbine (NVBo) and cisplatin (P) with concomitant radiotherapy (RT) followed by either consolidation (C) with NVBo plus P plus best supportive care (BSC) or BSC alone in stage (st) III non-small cell lung cancer (NSCLC): Final results of a phase (ph) III study.
Rudolf M. Huber
Research Funding - Pierre Fabre Medicament
Walburga Engel-Riedel
No relevant relationships to disclose
Jens Kollmeier
Consultant or Advisory Role - Boehringer Ingelheim (U); Lilly (U); Roche (U)
Stefan Andreas
Honoraria - Roche
Susanne Staar
No relevant relationships to disclose
Gunther Klautke
No relevant relationships to disclose
Rainer Fietkau
Consultant or Advisory Role - Pierre Fabre Medicament
Honoraria - Pierre Fabre Medicament
Research Funding - Pierre Fabre Medicament
Expert Testimony - Pierre Fabre Medicament (U)
Nathalie Vaissiere
Employment or Leadership Position - Pierre Fabre Medicament
Susanne Osowski
Employment or Leadership Position - Pierre Fabre Medicament
Stock Ownership - Pierre Fabre Medicament
Michael Flentje
No relevant relationships to disclose